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PEMBANGUNAN DERIVATIF- DERIVATIF ASID ROSMARINIC 
UNTUK MENSASARKAN IL17A BAGI GLIOBLASTOMA MULTIFORME 
MELALUI LALUAN ANGIOGENIC  
 
ABSTRAK 
Di sini, kami memanfaatkan perencatan glioblastoma melalui kesan IL17A, 
melalui penyekatan angiogenesis, menggunakan derivatif baru asid rosmarinic (RA). 
Aktiviti anti-GBM sebatian ditentukan melalui penghijrahan sel, pertumbuhan dalam 
sel-sel U87 MG, DBTRG MG dan EA.hy926. Aktiviti anti-angiogenik telah 
ditentukan oleh pembentukan tiub, CAM, dan ujian eksplan aorta. Aktiviti sebatian 
IL17A dan ekspresi VEGF telah ditentukan dengan menggunakan ELISA, dan aktiviti 
apoptotic dinilai oleh assai Caspase. Laluan kanser telah ditentukan dengan 
menggunakan assai pelapur gen. Derivatif menunjukkan > 2 kali ganda 
kebolehtelapan halangan darah-otak, daripada asid rosmarinik. ROS telah terzahir 
berasingan selepas rawatan dengan garam dan bes rosmarinate dalam sel U87 MG. 
IC50 garam perak ditemui > 1200 μg / ml, yang tidak boleh ditakrifkan sebagai 
sebatian toksik. Nar dan FLVM menjejas ekspresi gen PRB-E2F dan MAPK / ERK, 
dengan masing-masing, 1.03 kali ganda dan 1.14 kali ganda, penurunan. IL17A, 
VEGF dan protin-protin HIF1α telah dihalang dengan ketara; 2 kali ganda untuk NaR 
dan AgR, dan 1.5 kali ganda untuk FLVM (P < 0.0001). Kami mendapati bahawa 
pengdeaktifan gen dan protein ini, menyediakan keberkesanan terapeutik melalui 
aktiviti anti-angiogenik yang diperolehi; 44.01 ± 4.1%, 63.80 ± 4.3%, 61.65 ± 3.9%, 
dan 46.45 ± 2.8% daripada ciri-ciri anti-migrasi dalam sel-sel U87 MG (P < 0.05); 
59.83 ± 1.85% , 60.56 ± 4.2%, 79.56 ± 3.65%, 97.34 ± 4.5% daripada ciri-ciri 
antimigrasi dalam sel-sel EA.hy926 (P < 0.05); 69 ± 2%, 95 ± 4%, 81 ± 6.8%, 82 ± 
7.8% daripada perencatan pembentukan tiub (P < 0.05), dan 86.59 ± 3.45%, 49.69 ± 
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2.84%, 89.92 ± 4.56%, 58.22 ± 6.47% daripada kesan pencegahan eksplan saluran 
darah (P < 0.05), masing-masing untuk Nar, AGR, FLVM dan FLVZ pada dos-dos 
yang tinggi. Kami memerhatikan penurunan ketara penanda-penanda-bio apoptotik 
Bad, Bcl-2 dan Bcl-w dengan 6.53, 1.28 dan 3.97 kali ganda. Pengurangan saiz tumor 
glioblastoma dan pengambilan makanan haiwan telah diperhatikan, selepas rawatan 
dengan derivatif-derivatif  RA. Keberkesanan anti-glioblastoma (ΔT / ΔC%) NaR, 
AgR, FLVM dan FLVZ, telah didapati masing-masing sebagai 24%, 47%, 2% dan 
11%. Kesimpulannya, keputusan- keputusan kajian ini menunjukkan bahawa RA dan 
derivatif-derivatifnya mempunyai aktiviti antiglioblastoma, dengan mensasarkan 
ekspresi IL17A dan VEGF, dan sebatian-sebatian tersebut juga menyekat beberapa 

















THE DEVELOPMENT OF ROSMARINIC ACID DERIVATIVES TO 




In this study, glioblastoma inhibition was acheived via the disruption of 
IL17A, which blocks angiogenesis using new derivatives of rosmarinic acid (RA). 
Anti-GBM activity of the compounds were determined through cell migration and cell 
proliferation assays with U87 MG, DBTRG MG, and EA.hy 926 cells. Antiangiogenic 
activity was investigated with tube formation, CAM, and aortic explant assays. The 
compounds’ activity in IL17A and VEGF expression was determined using ELISA 
and their apoptotic activity was assessed by the Caspase assay. The cancer pathway 
was determined using the reporter gene assay. These derivatives showed >2 fold 
blood-brain barrier permeability compared to that of rosmarinic acid. ROS were 
differentially expressed after treatment with salt and base rosmarinates in U87 MG 
cells. The IC50 of silver salts was found > 1200 µg/ml, which defined them as non-
toxic compounds. NaR and FLVM affected the expression of pRb-E2F and 
MAPK/ERK genes with 1.03-fold and 1.14-fold downregulation, respectively. The 
expression of IL17A, VEGF, and HIF1α proteins was significantly inhibited, 2-fold 
for NaR and AgR and 1.5-fold for FLVM (P<0.0001). It is found that inactivation of 
these genes and proteins provided therapeutic efficacies of antiangiogenic activity at 
44.01±4.1%, 63.80±4.3%, 61.65±3.9%, and 46.45±2.8% of antimigratory properties 
in U87 MG cells (P<0.05), 59.83±1.85%, 60.56±4.2%, 79.56±3.65%, 97.34±4.5% of 
antimigratory properties in EA.hy926 cells (P<0.05), 69±2%, 95±4%, 81±6.8%, 
82±7.8% of inhibition of in tube formation (P<0.05), and 86.59±3.45%, 49.69±2.84%, 
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89.92±4.56%, 58.22±6.47% of vessel explant prevention (P<0.05) for NaR, AgR, 
FLVM, and FLVZ at high doses, respectively. The downregulation was observed for 
Bad, Bcl-2, and Bcl-w apoptotic bio-markers at 6.53-fold, 1.28-fold and 3.97-fold 
activity. The in-vivo glioblastoma study using NaR, AgR, FLVM, and FLVZ did not 
show any drug related adverse effect . The antiglioblastoma efficacy (ΔT/ΔC%) of the 
NaR, AgR, FLVM, and FLVZ were found to be 24%, 47%, 2%, and 11%, respectively 
(P<0.0001). In conclusion, the result of this studies shows that  RA and its derevatives 
have potent antiglioblastoma activity by targeting the IL17A and VEGF expression, 
and the compounds also blocked a variety of different namely the apoptotic, 







1.1 Glioblastoma, pathology and therapy 
Despite many treatment options, cancer remains a growing problem and has 
become the second leading cause of death globally. Cancer refers to the excessive, 
uncontrolled growth of abnormal cells, which can invade and eventually destroy other 
tissues. Furthermore, it can develop in any organ of the body and is life threatening. 
Notably, each year, more than 5 million people die of cancer (American Cancer 
Society). Glioblastoma multiforme (GBM), or "glioblastoma" according to the World 
Health Organization (WHO) classification, also known as Grade IV Astrocytoma is 
the most common and most aggressive malignant primary brain tumor in humans 
involving glial cells, and accounts for 52% of all functional tissue brain tumor cases 
and 20% of all intracranial tumors. Moreover, Glioblastoma is the primary form of 
brain tumor with approximately 23,000 newly diagnosed cases each year in the United 
States (Dolecek et al., 2009), while also having a dismal median survival of only 14-
15 months (Stupp  et al., 2009). In Malaysia, approximately 38000 people die from 
cancer each year (Malaysia Cancer Index), whereas the incidence of brain and nervous 
system tumor amounted to 3.3 per 100,000 people (CR) in 2006, as reported by the 
Malaysian National Cancer Council (MAKNA). GBM is rare and is classified as two 
categories, either giant cell glioblastoma or gliosarcoma, with incidences of 2–3 cases 
per 100,000 in Europe and North America (Louis et al., 2016). The rate of occurrence 
of GBM varies with gender, race, and geographic region. Children under the age of 
15 are more frequently diagnosed with primary brain tumors than those between 15 
and 19. The survival rate of GBM is low, but early detection accompanied by lifestyle 
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changes can extend the life expectancy of these patients. Recent research on GBM has 
provided better understanding of this disease as well as new and better treatment 
options such as chemotherapy, radiation and surgery. However, treatment of GBM 
with standard-of-care radiation and chemotherapy with temozolomide or 
Bevacizumab is still low, with median survival of 15 months. 
 
1.2 How cancer develops 
The human body consists of 30 trillion cells which undergo a regular life cycle, 
with cell death and renewal. This process is tightly regulated in a precise and orderly 
fashion. Healthy cells have a controlled division system named mitosis, which ensures 
the needed cell duplication according to the necessity of the organ and tissue in order 
to maintain their shape and size (Peterson, 2009). Uncontrolled cell division, however, 
cannot be prevented by normal biological cell functions when system of detection and 
action cannot work properly. This improper regulation of cell division induces anti-
apoptotic signals on the cells, which then can become cancerous. The birth of 
cancerous cells happens inside the genetic makeup or genome of cells, at the level of 
individual genes, each on its own, a biochemical instruction to produce each protein 
in the human body. In fact, the genome is composed of tens of thousands of these 
genes each encoded into a coiled molecule named deoxyribonucleic acid (DNA) 
(Peterson, 2009). Genes consist of specific information to make proteins, the very 
building blocks of cells and controllers of virtually all biochemical and enzymatic 
reactions in the cells. However, protein function is lost or altered through gene 
mutation, which can lead to uncontrolled growth, thus inducing formation of tumor 
masses and cancer development. In this mechanism, cells communicate with each 
other via receptors on the cell surface, which transfer signals by releasing pro-divide 
growth factors. This signal diffuses into the nucleus where genes are located, which 
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then activates the proto-oncogenes to cause mutation in normal cells.  in normal cases, 
growth signaling goes to nucleus and induces growth pathways in the genome, 
however when there is mutations in the pathway, the growth signaling can be hyper 
activated or sustained in absence of outside stimulus. This mutation signaling activity 
permits the growth and division of the cells repeatedly with or without the growth 
factors. In addition, tumor suppressor genes, which halt growth, can become mutated 
due to carcinogenic factors thus stopping their growth inhibitory activity (Peterson, 
2009). The cause of tumor formation is not only the mutation of tumor suppressor 
genes, but also of other safety mechanisms in the cells. Furthermore, abnormal cell 
cycle function or abnormal timing of the biological clock through different mutations, 
could, via inactivating and activating proto-oncogenes and tumor suppressor genes 
respectively, while in a healthy cell could derail the cells normal division leading to 
cancer formation (Peterson, 2009). In normal cells, the clock mechanism can detect 
impaired cycling activity and can seek to repair it by triggering the tumor suppressor 
gene p53 in order to provide pro-apoptotic signals to stop uncontrolled cell division 
(Peterson, 2009). Unfortunately, in cancer cells for example, p53 might be mutated 
due to carcinogenic effects, thus this safety mechanism could not function. Lacking 
these safety mechanisms, cells continue to replicate, which could also lead to improper 
DNA amounts in cells. Normal cells can undergo roughly 40 cell divisions, after 
which “telomeres” become too short, which could lead to loss of DNA sequences in 
subsequent replication cycles which ultimately kills the cells. These telomeres or 
sequences at the end of DNA to protect them and work to regulate irregular cell 
division. In cancer cells, the telomerase enzyme responsible for lengthening the 
telomeres, an enzyme usually only active in the germline, is re-expressed which leads 
to cells “immortality” thus perpetuating the uncontrolled duplication of cancer cells. 
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However, the circumstances above (i.e. gene mutation and telomerase reactivation) 
are not on their own sufficient for the development of cancer, because a combination 
of other biological obstacles need to be overcome.  
 
Normal cells build up a fibrous meshwork called the extracellular matrix on which 
to grow and form organs and other complex tissues and cannot survive without this 
matrix, while cancer cells can live without it. This irregular growth of cancer cells 
forms tumors which can grow on top of each other, creating a mass of cells. Also, 
unlike normal cells, tumor cells can develop their own network of blood vessels to 
supply the blood, a process called angiogenesis (Peterson, 2009).  
 
Tumors may be benign or malignant depending on their tissue invading 
capabilities. Benign tumors cannot invade normal tissues and are limited to one site 
but malignant tumors can invade normal tissues and travel to distant locations in the 
body through the blood vessels. Tumor cells then can pass into the lymphatic system 
and metastasize. While circulating, tumor cells home towards tissues expressing 
compatible receptors, thus leading to tumor metastasis in specific tissues. During this 
metastatic phase of cancer, many cells die in the bloodstream or become dormant and 
again start to grow, for reasons not yet known (Peterson, 2009).  
 
1.3 Causes of cancer 
The causes of cancer are not yet fully understood, but general causes include life 
style, chemical exposure, environmental, pathological factors and in addition the 
inclination of some people to develop the disease more than others. Prolonged 
exposure to carcinogens from chemical, biological and physical industry causes the 
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cellular damage in personnel and this exposure might increase the production of free 
radicals in the body which are known to damage DNA by taking negatively charged 
particles i.e. electrons which cause mutations. Smoking is another cause of cancer 
related to lung, oesophagus, respiratory tract, bladder, pancreas, and that might be 
cancers of the stomach, liver, and kidneys (Peterson, 2009). In addition, obesity can 
increase the likelihood of developing cancer and some microorganisms such as human 
papillomavirus (HPV), Hepatitis B and C viruses, Epstein-Barr virus, Human 
Immunodeficiency Virus (HIV), Helicobacter pylori, and polyomavirus are linked to 
cancers in the cervix, liver, lymphatic system, circulatory system, stomach and skin 
cancer, respectively (Peterson, 2009). People in third world countries are suffering 
from liver cancer and bladder cancer due to infections of parasitic organism such as 
Clonorchis sinensis and Schistosoma haematobium. Environmental factors such as 
sunlight, X rays, and ultraviolet (UV) radiation, working in radioactive mines and 
radon gases have been linked with skin cancer (Peterson, 2009). Additionally, 
pollutants in the air, soil and water are linked with bladder cancer. In the chemical 
industry, personnel are exposed to carcinogenic chemicals such as benzene, asbestos, 
vinyl chloride, aniline dyes, arsenic, and certain petroleum products (Peterson, 2009). 
Consistently, cancer is developed due to some genetic mutations in tumor suppressor 
genes of BRCA1 or BRCA2 for breast cancer at the age of 70 and the mutations of 
MSH2, MLH1, PMS1, and PMS2 genes are major players in colon cancer (Peterson, 
2009). Breast and uterine cancer are also developed due to long exposure of estrogen 
hormones. Other reasons for breast cancer are early menstruation, late menopause, no 
children, or having children after the age of 30. In addition, male testosterone also 
plays a role in the developing of cancer in the male reproductive organs. Statistics 
show that black women have a lower risk of developing breast cancer compared to 
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white women. Furthermore, Hispanic, Asian and North American women have the 
lowest risk for breast cancer worldwide, while African American men are more likely 
to develop cancer, thus demonstrating the impact of genetic makeups on the 
propensity for developing cancer. 
 
1.4 Types of cancer 
More than 100 types of cancers are found in various organs of the body. The nature 
of cancer is defined based on the origin of the cancer, how it first formed and the types 
of cells involved in the tumor. In addition, metastasis in a tissue are not defined as 
new cancers but rather metastatic cancers of the original tumor type. For example, 
breast cancer describes any cancer that originated in the breast. If the cancer spreads 
to a new organ, such as the lungs, the lung tumor is named metastatic breast cancer, 
rather than lung cancer. Most cancer patients suffer from cancers of the prostate, 
breast, lung, colon, lymphoma, bladder, uterine, skin, kidney, leukemia, pancreas, 
ovaries and stomach.  
 
1.5 Treatment 
Treatment of cancer is dependent on the type and stage of the tumor development. 
Several treatments have been created to treat cancer however no magic pill cure for 
cancer exists. These treatments include surgery, radiation, chemotherapy and 
immunotherapy, which have been shown to extend the life expectancy of patients. 
Early detection of any tumor may provide a higher scope in eradicating the chance of 
cancer development. The detailed recent therapeutic information can be found at 




1.6 Angiogenesis and cancer 
Tumors develop their own network of blood vessels, a process called 
angiogenesis. Angiogenesis is a normal process in the body which is classified as pro- 
and anti-angiogenic factors. There is a balance in normal tissue between pro- and anti-
angiogenic growth factors which is defined as an angiogenic switch (Hananah and 
Folkman, 1996). This natural balance can stimulate vascular growth when necessary. 
The principle angiogenic factor is vascular endothelial growth factor (VEGF). Other 
factors involved in this process are transforming growth factor-α (TGF-α), hepatocyte 
growth factor (HGF), Basic fibroblast growth factor (bFGF), angiopoietin-1 (Ang-1), 
angiopoietin-2 (Ang-2), platelet derived growth factor (PDGF), matrix 
metalloproteinases (MMP), and placenta growth factor (PlGF) etc (Peterson Karen, 
2009). The angiogenic switch is controlled by inhibition of these pro-angiogenic 
factors by some endogenous anti-angiogenic factors, namely endostatin, angiostatin, 
and thrombospondin-1 (Tsp-1), by promoting apoptosis. Further, angiogenic growth 
factors are influenced by the hypoxia in the tumor microenvironment.  This 
environmental response is activated by the Hypoxia induced growth factor 1α (HIF-
1α) (Naumov et al., 2008; NIH, 2009). Normally, HIF-1α is ubiquitinated in the 
presence of von Hippel-Lindan tumor suppressor (pVHL) protein. This HIF-1α 
protein is then degraded, thus stopping its signaling, but this degradation is stopped 
under hypoxic condition where HIF-1α  interacts with the p300 and cAMP responsive 
element binding protein (CREB) proteins. The HIF-1α complex enters into the 
nucleus and heterodimerizes with HIF-β, which transcripts the genes of interest 
(Courtwright et al., 2009; Kang et al., 2009; Ribatti et al., 2007; Wouters et al., 2008; 
Land and Tee, 2007). HIF-1α can induce the expression of growth factors of VEGF, 
PDGF, and TGF-α by binding with the hypoxia responsive element the promoters of 
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these growth factor genes and inducing their expression.   Other factors such as 
mammalian target of rapamycin (mTOR) can also interact with HIF-1α  (Vadysirisack 
and Ellisen, 2012). This signaling molecule forms a complex which is phosphorylated 
and affects cell growth. Hypoxia also regulates mRNA translation and promotes 
tumor formation. Pro-apoptotic factors such as BH-interacting domain death agonist 
(BID), Bcl-2 antagonist of cell death (BAD), and Bcl-2 associated X protein (BAX) 
are inhibited in hypoxic conditions. This increases the cell-life span and tumor growth. 
VEGF signals cells to form capillary-like blood vessel structures with the aid of 
endothelial cells and to damage the extracellular matrix with some enzymes.  VEGF 
is expressed and helps to induce the anti-apoptotic proteins Bcl-2 and its homolog A1-
10 VEGF receptors (VEGFR). VEGFR phosphorylates tyrosine residues on several 
targets to activate downstream signal transduction molecules. Tumor 
microenvironment stimulates angiogenic factors to attract the endothelial cells to 
grow the blood vessels surrounding the tumor. The mechanism of vessel growth is 
discussed below.  
 
Embryonic development of neovascularization of tumor angiogenesis is 
defined as vusculogenesis that is developed through endothelial cell production from 
angioblast. Characteristically, vusculogenesis induces varieties of angiogenic signals 
from preexisting blood vessels. Endothelial cells produce proangiogenic factors to 
form the provisional tubes and novice perivascular cells which provide them maturity 
and stability. Usually, tumor angiogenesis induces a progression of new vessels from 
preexisting vessels and the tumor recruits signal from the bone marrow and tumor 
stem cells (Herbert and Stainier, 2011) to induce the formation of more blood cells. 
The tumor functional network effects the disease development and creates short term 
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effects via different signaling molecules and vascular renovation, wherein suppression 
of one pathway can stimulate others. Termination of this vascular network has been a 
therapeutic strategy as an anticancer target. Controlling the signaling pathways of 
neovascularization in downstream signaling molecules could be the new strategy to 
suppress angiogenesis. The continuous progression of the tumor lesion is influenced 
by hypoxia and nutrient deprivation, which can generate more angiogenesis for further 
survival of tumor cells. Different kinds of cytokines and growth factors are released 
from the tumor microenvironment to activate different cascades of angiogenic events. 
For example, VEGF is released from the tumor which stimulates endothelial cell 
proliferation. On the other hand, PDGF stimulates perivascular cells and modulates 
vascular stability and growth of tumor (Weis and Cheresh, 2005). Moreover, 
development of the tumor vascular bed is driven through tumor associated fibroblasts 
to provide the extracellular matrix (ECM) proteins. Tumstatin and endostatin act as 
endogeneous inhibitors against angiogenesis through inhibition of ECM proteins. 
Targeting of angiogenesis signaling proteins needs an anti-angiogenic efficient drug 
with complementary effect of systematic apoptosis (Franco et al., 2010; Demaria et 
al., 2010; Grivennikov et al., 2010).  
 
In angiogenic processes different independent and interdependent factors are 
observed such as Notch, semaphorins, ephrine and slits which are GF family proteins 
comprised of SLIT1, SLIT2, and SLIT3 ligands. These ligands are recognized by 
ROBO1, ROBO2, ROBO3 and ROBO4 receptors (Jones et al., 2008). Tumor cell 
expresses these ligands and their receptors as paracrine and autocrine factors. 
Guidance molecules are activated through their receptors that recruit progenitor cells, 
which induce the tumorigenic process through macrophage signaling pathway. 
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Potential anti-angiogenic ligands can bind to these receptors to inhibit other 
angiogenic signaling pathways. For example, ROBO4 inhibits VEGF and FGF 
pathways and thus the mechanism of guidance molecules in angiogenic activity and 
their role with other angiogenic growth factors might be a potential therapeutic 
strategy (Park et al., 2003; Zygmunt et al., 2011). Furthermore, integrins are another 
type of ECM protein which can control the angioganic cascade. Integrins are primary 
cell matrix protein with which other ECM intracellular signaling pathways are 
controlled. It has α and β subunits which can bind with multiple ECM proteins. 
Ligation of integrin mediated signaling could crosstalk between integrin and other 
activated cytokines (Kim et al., 2011). Conversely, the overexpression of integrins 
can promote the proteolytic activation of ECM protein which increases the 
endogenous angiogenesis through matrix formation. Recent studies have shown that 
cyclic peptide could trigger βvα3 type integrin to block angiogenesis. Expression of 
βvα3 can increase tumor growth and metastasis. It was also found that high grade 
glioblastoma brain tumor overexpress βvα3 receptor and ECM vitronectin. Also, cyclic 
peptide antagonist shows potential inhibitory activity against orthotopic glioblastomas 
in mice model. Cilengitide is the first integrin antagonist approved by the US food 
and drug administration (FDA) for cancer therapy currently in under clinical trial. 
Additionally, proangigenic integrins are currently considered for clinically effective 
anticancer drugs which might target αv, αvβ3, α5β1, αvβ3 αvβ5 and α5β1 coupled with 
Arg-Gly-Asp (Desgrosellier and Cheresh, 2010). Cross talk between integrin and GF 
receptors are widely studied recently. VEGF, FGF, PDGF and angioprotein are 
proangiogenic proteins and each of them has specific isoform such as VEGFA-121, 
VEGFA-165, VEGFA-189 and VEGFA-206. The activity of VEGF receptors such as 
VEGFR1, VEGFR2 are modulated by clustering or dimerization of these receptors. 
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Integrin and GF signaling proteins show an interaction between αvβ3 with VEGFR2, 
HGFR c-Met, FGFR1, PDGFR, EGFR and IGF-1R. The prevention of this interaction 
could reduce the angiogenesis in tumor (Meyer et al., 2011).  
 
Extra cellular matrix proteins are crucial for controlling angiogenesis because 
MMPs such as MMP-2, MMP-9, MT1-MMP trigger the angiogenesis process via the 
destruction of ECM proteins. MMP mediated degradation can affect cryptic Arg-Gly-
Asp sites of integrin proteins against sprouting of endothelium that selectively can 
damage ECM remodeling. Understanding the mechanism of the MMP enzymes could 
be another therapeutic strategy to target tumor angiogenesis (Deryugina and Quigley 
et al., 2010; Sounni et al., 2011). 
 
MicroRNAs is another kind of small noncoding RNA which can act as an 
angiogenic switch for vascular developments through protein translation regulation. 
Different kinds of RNA binding proteins regulate miRNA function by controlling 
biogenesis. Targeting of miRNA could not be selective therapeutic approach because 
of its direct relationship with tumor suppressor genes. VEGF expression competitively 
depends on miRNA function (Huynh et al., 2011). Recently, some angiogenesis-
controlling miRNA called angiomiRs were identified. MiR-126, miR-130a, miR-210 
and miR-296 stimulate angiogenesis whereas miR-221 and miR-222 suppress tumor 
angiogenesis. These angiomiRs regulate migration, proliferation, and hypoxia of 
tumor cells and targeting of angiomiRs could be a potential target to control cancer 
progression. The angiomiR mir-126 controls angiogenesis by upregulation of 
miRNAs, which regulates the angiogenic switch by suppressing tumor promoting 
genes. miRNA inhibitors can decrease the miRNA expression and control angiogenic 
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response. Such is the case for example pertaining to the involvement of miR-132 in 
inducing the endothelial proliferation through p120RasGAP expression. Anti-miR-
132 therapy could inhibit endothelial cell proliferation via affecting p120RasGAP 
expression and suppression of Ras activity. In breast cancer cell, miR-20b regulates 
VEGF expression by triggering HIF-1α. miR-93 reduces expression of αvβ8 integrin 
in glioblastoma cell which results in the growth of endothelial cells to promote 
angiogenesis. Blocking of angiogenesis using anti-miRNA therapy requires delivery 
of new RNA into the tumor as the therapeutic approach. However, recent study 
showing the use of such therapy through adenovirus-mediated miRNA delivery have 
revealed that the therapy might have some potential efficacy in preclinical models but 
its application in humans might be complex because miRNA or anti-miRNA delivery 
needs further validation in better disease models. In addition, preparation of 
nanoparticles containing the anti-miRNA molecules could be an interesting delivery 
mechanism into the tumor cells, but overall, further development is needed to address 
the use of miRNA therapy (Murphy et al., 2008). 
 
Anti-angiogenic therapy does not only block signaling pathways but also 
provides inverse effects to other cells. Co-culturing of endothelial cell and smooth 
muscle cell shows potential inhibition of cell proliferation but this study shows that 
after treating the cells, endothelial cell pericyte could be reformed for further survival 
of cell and thus this strategy might not suitable for cancer cell. In addition, inverse 
effects of anticancer therapy are a particular problem in integrin and miRNA-
associated tumorigenesis. Although a similar dichotomy exists in VEGF associated 
tumorigenesis, VEGF-inhibited VSMC activity shows potential PDGF inhibition of 
angiogenesic processes, and that VEGF activated VEGFR2 could induce PDGFRβ 
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signaling through interaction of VEFR2-PDGFRβ complex. This mechanism 
postulates that the use of anti-angiogenic therapy might provide complementary 
efficacy by inducing cancer cell apoptosis by inhibiting the proangiogenic cytokines 
(Hu et al., 2009). Further, antibody therapy have shown efficacy in the inhibition of 
endothelial cell migration and tumor infiltrating growth factors in esophageal cancer. 
Despite the usefulness of antibody therapy, further investigation is warranted to 
authenticate its clinical efficacy in tumor microenvironment (Chung et al., 2010, Lu 
et al., 2000). The discovery of angiogenesis pathways has helped to develop many 
FDA-approved anticancer and anti-angiogenic drugs, such as avastin, sorafenib, and 
sunitinib that target VEGF-A, Raf and PDGF, respectively. It is notable that 
combination therapy could be good strategy to block angiogenic signaling pathways 
and to prevent high levels of mutation and survival factors in the tumor. To improve 
the anticancer drug efficiency, anti-VEGF drugs are administered with 
chemotherapeutic agents to provide high clinical potency. The perivascular 
compartment could also be beneficial for treating angiogenesis due to its activity in 
vessel maturation and blood flow (Hu et al., 2009; Chung et al., 2010; Azzi et al., 
2013). 
 
The tumor blood vessels can stimulate the tumor microenvironment and 
govern the mutated signaling pathways. Tumor-associated endothelial cells show 
more differential properties than normal endothelial cells which is a useful tool to 
detect the cancer for targeted therapies, and many methods are being developed to 
identify the cancer using the tumor associated vasculogenesis properties. The results 
of flow cytometry and magnetic bead separation show that tumor cells attract the 
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endothelial cells to increase angiogenesis, survival activity, immortality and 
chemoresistance activity.  
 
Many studies show that angiogenesis and immunosuppression instantaneously 
occur instantaneously during aseptic tissue injury resulting from ischemia, reperfusion 
injury, infection and pregnancy. This dual biological changes is found in tumor 
microenvironment and is initiated by the induction of complex cellular processes. 
Myeloid cells promote immunosuppression and angiogenesis in tumors and myeloid 
derived suppressor cell (MDSC) are noticeably increased in tumor patients (Motz GT, 
and Coukos G., 2011). This has been shown to be mediated through T and NK cell 
activation and results the high level of NO, ROS, interlukin-10, transforming growth 
factor-β (TGFβ). It has been demonstrated that MDSC can directly promote 
angiogenesis and thus a study designed to target the MDSC shows that treatment with 
BV8 antibody deceased MDSC in the tumor-bearing mice.  Some myeloid cell subsets 
promote angiogenesis, plasmacytoid DC, tumor associated macrophages (TAM) and 
monocytes mediated angiopoetin (Bourbie-Vaudaine et al., 2006) which have the 
ability to promote expression of VEGF, FGF, CXC-chemokine ligand 8 and COX2, 
thereby upregulating the immune-stimulatory factors such as lymphocytes cell 
secreted cytokines. It has been suggested that CD+CD25+FOXP3
+TReg cells can make 
home to tumor sites and play a role in hypoxia induced angiogenesis in ovarian cancer 
progression. The TReg complex (receptor complex) can upregulate the expression of 
CC-chemokine ligand 28 (CCL28) to recruit CD4+CD25+FOXP3
+TReg cells from 
peripheral blood flow. Overexpression of CCL28 can recruit TReg through increasing 
angiogenesis and immunosuppressive microenvironment via VEGFA. VEGFA 
induces hypoxia through CD4+CD25+TReg and promotes cell proliferation. In addition, 
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CD4+T cells induce the expression of  neuropilin 1 (NRP1) in dendritic cells (DC) 
through trogocytosis (Facciabene et al., 2011; Sarris et al., 2008). DC then secrete 
VEGFA in tumor sites and increases angiogenesis. Other immune cell subsets include 
B cell, Natural killer T (NKT) cells, NK cells, γδ T cells have been shown to produce 
VEGFA. Mesenchymal stem cells (MSC) are a type of stromal cells that can secrete 
VEGFA by differentiating cancer associated fibroblast (CAF). MSCs promote 
angiogenesis by secreting VEGFA, thus inducing the differentiation of CAFs which 
express α-smooth muscle actin, and TIE2. Total contribution of MSCs is unknown 
but it has an integral role in the establishment of the tumor microenvironment, 
supporting both immunosuppression and angiogenesis. Stromal CAF cell are 
activated by TGFβ, FGF, and PDGF and can secrete VEGFA to promote the 
recruitment of cells of the myeloid lineage through CCL2 and CXCL12 activation.  
VEGFA can control a varied assortment of immune functions and serves as a 
prototypical molecules to mediate angiogenesis. The overexpression of VEGFA by 
tumor cells can produce high intratumoural TReg cells in order to provide tolerogenic 
situation and tumor evasion (Bhowmick et al., 2004). 
 
Endothelial cells (ECs) can regulate immune cells by controlling leukocyte 
trafficking by inducing leukocyte extravasation to the tumor site. This activity of ECs 
is mediated through intercellular adhesion molecule 1 (ICAM1) and vascular cell 
adhesion molecule 1 (VCAM1).  ICAM1 and VCAM1 can moderate the adhesion and 
migration of leukocytes. VEGFA and bFGF can increase the adhesion of T cells 
through tumor necrosis factor (TNF). TNF can increase the VCAM1 and ICAM1 
expression via Caveolin 1. T cells are involved in the activation of endothelium B 
receptor (ETBR) which is upregulated in ovarian cancer and causes inflammation and 
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a quiescent tumor endothelium phenotype. Tumor endothelial cells attract immune 
cells through tumor reactive TEff cells and NK cells. Furthermore, TReg cells migrate 
to the tumor via VEGFA and hepatocyte growth factor (HGF) signaling in hepatic 
carcinoma cells through ubiquitously expressed endothelial and vascular endothelial 
receptor 1. There are several mediators (signaling molecule) of endothelium including 
PDL1, PDL2, FAS ligand, TNF-related apoptosis inducing ligand (TRAIL) and 
endothelium cell marker CD31 which are responsible for extravasation of leukocytes. 
IL-6, IL-10, TGFβ and PGE2 are several of the endothelial cell mediators that can 
suppress immune response (Dirkx et al., 2003). T cell immunoglobulin domain and 
mucin domain protein 3 (MD3) are expressed in endothelium through the activation 
of signal transducer and activator of transcription 3 (STAT3). Endothelial cell can 
express ICOS ligand (ICOSL), CD40, CD58, CD80, CD86, CD137, MHC class I and 
class II molecules to upregulate angiostatic, and TH1 cell-associated cytokines. The 
angiogenic mechanism of these molecules is still not clear but many studies show their 
involvement in angiogenesis. Also, the mural cells, a type of vascular cells are 
involved in angiogenesis and immunosuppression for blood vessel formation and 
healing.  It is postulated that immunosuppression and angiogenesis require different 
growth factors and inflammatory cytokines depending on the expression of cellular 
signals to promote tumorigenesis. In hypoxic state of tumor, IL-6 synergizes with 
VEGFA expression through VTCN1 and promote immunosuppression, and TH17 
differentiation (Choi et al., 2004; Pucci et al., 2009). 
 
The tumor microenvironment can stimulate homeostatic tissue repair activity 
that can be reflected as either angiogenesis or immunosuppressive. The use of anti-
angiogenic therapy in combination with chemotherapeutic agents can potently affect 
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tumor growth and can reduce the side effects of the toxic drugs.  Moreover, lysate 
vaccine and ETBR therapy is currently being tested in preclinical model as a potent 
anti-angiogenic therapy. This vaccine is used with COX2 inhibitor and anti-VEGF 
antibody. Oxidized lipids which act as endogenous ligands for the TLR2-MYD88 
pathway, controls wound healing, ischemia and tumor angiogenesis by stimulating 
endothelium cells (Kiichiro Yano et al., 2006; Cavassani et al., 2010).   
 
1.7 Interleukin 17A, angiogenesis, inflammation and cancer  
Interleukin 17 comprises six members (IL17A – F) with the most heavily studied 
being IL17A. IL17A is produced by Th17 cells (Dong et al., 2008) and shows 
potential roles in promoting tumor angiogenesis and inflammation (Figure 1.1). In 
tumor pathogenesis, chronic inflammation has a significant role in inducing tumor 
growth (Coussens et al., 2002), wherein IL17A acts as proinflammatory factor in 
cancer patients (Fujino et al., 2003).  In the tumor, IL17A induces blood vessel 
formation and angiogenesis (Lemancewicz et al., 2012; Liu et al., 2011) and causes 
T-cell dependent tumor development and the Th17-produced IL17A increases the 




Figure 1.1 Effect of tumor cells in angiogenesis in the tumor microenvironment. 
Multiple factors are involved in the tumor-induced neovascularization. These 
factors (autocrine and paracrine growth factors) transform the normal epithelial 
cells into tumor cells. During this process, hypoxia inducible factor HIF1α and 
HIF1β trigger angiogenesis processes. As a result, tumor cells release soluble 
factors, cytokines and inflammatory cytokines (IL17A, IL6, etc.) to induce the 
sprouting, proliferation and migration of quiescent endothelial cells near the blood 






IL17A is also, termed as cytotoxic T-lymphocyte–associated antigen 8 (CTLA–8) 
(Rouvier et al., 1993) which is mainly produced by the activated CD4 T cells (Yao et 
al., 1995) and induces the expression of IL-6, IL-8, prostaglandin E2 (PGE2), and 
intercellular adhesion molecule 1 (ICAM–1) (Yao et al., 1995; Fossiez et al., 1996; 
Aarvak et al., 1999). Moreover, IL17A induces a higher expression of tumor necrosis 
factor α (TNF–α), IL-1 and stromelysin by macrophages (Jovanovic et al., 1998). This 
in turn, activates IL-17R (type 1 transmembrane protein) leading to activation of the 
transcription factor nuclear factor B, and regulation of extracellular-regulated kinase 
1 (ERK1), ERK2, c-Jun N-terminal kinase (JNK), and p38 mitogen–activated protein 
kinases (Yao et al., 1995; Shalom-Barak et al., 1998; Awane et al., 1999). There are 
some homology between IL17A members but, IL17AR has no homology making it a 
novel receptor family. Although the expression of IL17A is found in normal and 
cancer cells, the particular activity in cancer is not clear yet. CD4 T cell derived IL17A 
is stimulator of angiogenesis and has a potential role in neovascularization via 
migration of endothelial cell and cord formation. IL17A might have an indirect or 
direct proangiogenic effects in the tumor microenvironment by inducing TGF-β and 
PDGFb (Brogi et al., 1994). IL17A also has role in fibroblast-induced neovessel 
formation in inflammation and tumors and fibroblasts have been shown to modulate 
hypoxia and thereby tumor inflammation (Volpert et al., 1997; Cho et al., 2000). 
However, IL17A provides pro-angiogenic activity in tumors according to the 
immunogenicity and types of tumor cells. The development of tumors through 
angiogenesis is mainly regulated because of alteration of these pro- and anti-
angiogenic factors by the influence of IL17A which causes an imbalance of 
angiogenesis factors and growth factors in the vascular microenvironment. This 
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activity of IL17A could be controlled by targeting the CD4 T cell derived IL17A in 
the tumor microenvironment.   
 
1.8 Interleukin 17A and glioblastoma multiforme: pathology and treatment 
Glioblastoma Multiforme (GBM) is the most frequently occurring primary brain 
tumor. GBM progresses very quickly and patient’s median survival rate is 12 – 15 
months. Inflammation and angiogenesis have potential impacts on the formation of 
brain tumors (Guiton et al., 2010; Smith et al., 2010). In glioblastoma, IL17A 
signaling or elevated IL17A levels are observed due to the dysfunction of T helper 
cells (Andaloussi et al., 2008; Prahlad et al., 2013; Julian et al., 2013; Jinhui et al., 
2013) and infiltration of immunosuppressive microglia and macrophage cells (Watters 
et al., 2005). IL17A also activates platelet endothelial cell adhesion molecule 
(PECAM-1), also known as cluster of differentiation 31 (CD31) cells as well as the 
IL-6–STAT3 signaling pathway. It’s also been shown to suppress cytotoxic T 
lymphocytes by reducing their cytotoxic effect via the support of CD8 (Nam et al., 
2008; Toh et al., 2009; Wang et al., 2009; Stewart et al., 2006). The secretion of IL17A 
from astrocytes (Tzartos et al., 2008; Li et al., 2005) is augmented by the recruitment 
of Th17 polarized CD4+ T-cells (Brucklacher-Waldert et al., 2009; Hofstetter et al., 
2009), CD8+ T-cells, gamma delta T-cells (Sutton et al. 2009), NK-cells (Rachitskaya 
et al., 2008), and granulocytes (Li et al., 2010; Hoshino et al., 2008) to the central 
nervous system (CNS). This is further modulated by IL-23 signaling (Langrish et al., 
2010; Park et al., 2005; Harrington et al., 2005). In addition, TGF-b, IL-6, and IL-21 
have been shown to be the main causes of high expression of IL17A, this being 
produced due to the synergistic activity of Th17 cell in association with the pro-
inflammatory cytokines (Veldhoen et al., 2006; Bettelli et al., 2006; Mangan et al., 
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2006; Korn et al., 2007). IL17AR, which is expressed in the CNS on astrocytes, 
microglia and endothelial cells (Sarma et al., 2009; Kebir et al., 2007) activates 
NFkappaB and MAPK via TRAF6. The adaptor protein Act-1 is also activated (Chang 
et al., 2006; Qian et al., 2007), thereby further exascerbating inflammation  by the 
involvement of proinflammatory cytokines, chemokines and antimicrobial peptides 
such as G-CSF and the ELR+ members of the CXC family of chemokines CXCL1 and 
CXCL2 (Ouyang et al., 2008; Carlson et al., 2008; Fossiez et al., 1996; Kanget et al., 
2010) through the recruitment of neutrophils. Astrocytes, a subtype of glial cells 
demonstrate high expression of IL17A receptor through a synergistic interaction 
between IL-6 and IL17A, which activates the microglia in astrocytes (Kawanokuchi 
et al., 2008; Ma et al., 2010), mediated by the Act-1 (Kanget et al., 2010). In the 
inflammatory and tumor microenvironment, heat-shock protein 90 (Hsp90) and Act1-
interacting protein induce high levels of IL17A. IL-17 induced signaling and gene 
expression are abolished due to IL17A dependent phosphorylation. This 
phosphorylation is due to inhibition of Hsp90 chaperone function by the loss of 
interaction between Hsp90 and IL17A (Toh et al. 2009).  IL17A promotes the 
upregulation of pro-inflammatory and neutrophil-mobilizing cytokines and 
chemokines including JAK2/STAT3, MAPK, NF-κB, IL-6, IL-8, MMP2, VEGF, 
GM-CSF, GCSF, TNF-α, TGF-β and IL-1β. In addition, Cdc37, together with the 
chaperon Hsp90 can protect Akt from proteasome-mediated degradation (Sato et al., 
2000 and Basso et al., 2002) by forming the Akt-Hsp90 complex. A study by Wang 
et al. 2002 found both Hsp90 and Cdc37 in the IKK complex (Wang et al. 2012). 
Further, p23 acts as co-chaperone in the Hsp90 chaperon system, but is specific for 
steroid receptors and fibrillization of the protein. The above discussion postulates that 
the molecular targets for the inhibition of the IKK complex or inactivation of Cdc37 
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and p23, both co-chaperones of HSP90, might suppress the IL-17, IL-6 and VEGF 
activity. 
 
The inflammatory cytokines can invariably infiltrate the blood-brain barrier 
(BBB) and cause severe reactions by increasing inflammation and pain due to glioma 
growth. IL17A might penetrate the BBB by releasing reactive oxygen species (ROS) 
further enhancing angiogenesis and thereby blood supply to tumor (Chang et al., 2006; 
Huppert et al., 2010). Proinflammatory cytokines and chemokines are upregulated by 
the stimulation of IL17A (Cua et al., 2003; Kebiret al., 2007), thus mediating chronic 
and acute vascular inflammation. The relationship between the CNS vascular 
pathology and IL17A is mediated by malformations of arteriovenous and 
polymorphism of IL17A gene (Jiang et al., 2011). The vascular pathology is mediated 
by the TGF-β signaling as upstream regulator of IL17A (Bettelli et al., 2006; Mangan 
et al., 2006; Korn et al., 2007; Sarma et al., 2009). In addition, high expression of ROS 
in the brain endothelial cells downregulates occludin which is a vital signaling 
molecule in cellular tight junctions of blood vessels and brain cells, further increasing 
the permeability of IL17A to the brain and exacerbating the cycle in the tumor. 
(Huppert et al., 2010). Aside from the above molecular interaction of IL17A, it was 
shown that EGFRvIII is one of highly expressed potential molecules in GBM 
tumorigenesis and could be a potential target by inhibiting the IL17A,  IL-6 and IL-8 
activity (De Fazio et al., 2012).  
 
1.9 Natural compound as anti-angiogenic drug 
 Plant chemicals including secondary metabolites has been widely investigated 
for the treatment of angiogenesis based diseases. The most useful and studied natural 
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products are phenolic or polyphenolic compounds which show anti-angiogenic 
properties with potential anticancer efficacy. The mechanism of action of natural 
products was previously unknown which lead to their poor acceptance in main 
regulatory bodies. Recent observations however, and wide array of studies have 
shown their specific interference with biological targets at the molecular level, thus 
leading to a significantly increased rate of approval and use worldwide. In particular, 
natural phenolic chemicals such as flavonoids, rosmarinic acid derivatives, caffeic 
acid derivatives and diarylheptanoids are found to have potential anti-inflammatory 
activity, chemoprevention and cytoprotection activity have a pleiotropic influence on 
cellular signaling towards VEGF, NF-κB or Nrf2 and oxidative effects of cancer 
(Prasad  et al., 2010; Rahman et al., 2006; Pietta, 2000) (Table 1.1), all with minimal 
side-effects. Moreover, the natural chemicals found in many fruits and vegetable 
provide long-term health and nutrition due to their ample amounts in everyday foods. 
These phenolic chemicals have substantial benefits to health which reinforces a 
balanced angiogenesis in the human body. There are many excellent anti-angiogenic 
natural compounds found in vegetables containing a phenolic substructure. Among 
these compounds, six flavonoids from different subclasses: quercetin, fisetin, 
epigallocatechin-3-O-gallate, xanthohumol, (2S)-7,2’,4’-trihydroxy-5-methoxy-8-
dimethylallylflavanone and genistein have been highlighted here to discuss their 
potential anticancer effect through disruption of angiogenesis pharmacology (Table 
1.2). The angiogenic properties of the natural chemicals should be specific and non-
toxic, and potent enough to realistically speculate on the anti-angiogenic activity in 
vivo. The endothelial cells (ECs) are directly involved in the angiogenesis process due 
to a plethora of signaling cytokines from cancer tumors. These cells have thus been 
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given special attention for testing therapeutic efficacy of these anti-angiogenic 
compounds to verify for unspecific cytotoxic effects.  
 
Table 1.1 Natural phenolic compounds with anti-angiogenic activity and their 
evaluated molecular mechanisms of anti-angiogenesis (Qiu et al., 2015).  
 
Compound name Mechanisms of anti-angiogenic action 
4-Hydroxybenzyl alcohol Downregulation of VEGF and MMP9 protein 
expression 
Curcumin Reduction of VEGF expression, inhibition of 
transcription factors, mTOR pathway and 
MMP9 protein expression 
Ellagic acid Inhibition of VEGF and PDGF receptor 
phosphorylation 
Resveratrol Abrogation of VEGF-mediated tyrosine 
phosphorylation of vascular endothelial (VE)-
cadherin, inhibition of VEGF-induced and FGF-
2 neovascularization 
Quinoline-substituted phenols Inhibition of VEGF and Transforming Growth 
Factor-β1 (TGF-β1) expression 
4-Amino-2-sulfanylphenol 
derivatives 







Inhibition of estrogen-stimulated VEGF 
expression, HIF-1α and NF-κB, inhibition of 
MMP-2 and MMP-9, inhibition of urokinase 
plasminogen activator. 
Xanthohumol Inhibition of NF-κB and Akt pathways 
Genistein Inhibition of VEGF and HIF-1α protein 
expression 
Fisetin Downregulation of VEGF and eNOS 
expression, inhibition of MMPs function 
Quercetin Inhibition of the expression of VEGF-2, 
inhibition of COX-2 and arachidonate 5-
lipoxygenase (LOX-5), inhibition of NF-κB, In 




Downregulation of reactive oxygen species 
(ROS) levels and VEGF expression 
 
 
 
